LIANHE TECHNOLOGY(SZ:002250)2025-11-28 05:50Investment Rating - The report does not explicitly state the investment rating for Lianhe Chemical Technology (002250.SZ) Core Insights - The company has shown significant recovery in net profit during the first three quarters of 2025, with a revenue of 4.72 billion yuan, representing an 8.25% year-on-year increase, and a non-recurring net profit of 300 million yuan, up 1504% year-on-year, with a gross profit margin of 25.96%, an increase of 3.25 percentage points year-on-year [1] - The company is expanding its mature pharmaceutical business while investing heavily in new development directions, including the development of amino acids, peptides, and ADC/PROTAC linker synthesis services, which are expected to broaden its CDMO service offerings [3] - The agricultural protection market is recovering, with the company establishing a global supply chain through its Malaysian base, which is expected to start production within 1 to 2 years [3] - The new energy sector is set to contribute to future growth, with significant investments in lithium-related projects, including a planned capacity of 20,000 tons/year for lithium hexafluorophosphate and 10,000 tons/year for lithium bis(fluorosulfonyl)imide [3] Financial Data and Forecasts - Revenue projections for the company are as follows: 5.677 billion yuan in 2024, 6.406 billion yuan in 2025 (up 12.8% year-on-year), 7.425 billion yuan in 2026 (up 15.9% year-on-year), and 8.589 billion yuan in 2027 (up 15.7% year-on-year) [3] - The forecasted net profit for the company is expected to reach 103 million yuan in 2024, 403 million yuan in 2025 (up 290.3% year-on-year), 524 million yuan in 2026 (up 30.2% year-on-year), and 635 million yuan in 2027 (up 21.2% year-on-year) [3] - The earnings per share (EPS) is projected to be 0.11 yuan in 2024, 0.45 yuan in 2025, 0.58 yuan in 2026, and 0.71 yuan in 2027 [3]